Inthis solid-phasetwo-site enzyme immunoassay for hepatitis B surface antigen (HBsAg), three monoclonal anti-HBs are used: 503 (1gM)is immobilizedon plastic beads; 5C3 (IgG25)and 5C11 (IgG1), labeled with biotin, are used as the first conjugate. Horseradish peroxidase covalently linked to avidin is the second conjugate. First, serum or plasma is incubated with the antibody-coated bead and biotin-labeled antibodies, simultaneously, at 45 #{176}C for 1 h ("stat" procedure), 3 h ("standard" procedure), or 18 h ('overnight" procedure), during which HB5Ag forms a complex with the solid-phase antibody and the biotinylated antibodies. The enzyme-conjugated avidin is then bound to the biotin on the antigen-antibody complex at 45 #{176}C for 15 mm ("stat") or 30 mm (standard and overnight procedures). The beads are incubated with enzyme-substrate solution (H202 and ophenylenediamine). Color developed is measured at 492 nm.
Materials and Methods

Materials
Monoclonal
antibodies.
The establishment of somatic cell hybrids producing monoclonal antibodies to HBsAg designated 5D3, 5C3, and 5C11 has been described (3). 
Clinical samples.
Specimens from unselected healthy blood-bank donors were used.
Procedures
Antibody-coated beads and biotinylation of monoclonal antibodies.
Purified antibody 5D3 was coated on polystyrene beads (7 mm in diameter; Precision Plastic Ball Co., Chicago, IL 60641) according to the procedure of Ziola et al. (6) and dried. Purified antibodies 5C3 and 5C11 were labeled with N-hydroxysuccinimidobiotin (Sigma Chemical Co.) according to Clark and Todd (7) . Briefly, the antibody is dialyzed against borate-buffered (50 mmol/L, pH 8.6) isotonic saline and concentrated to 5.0 g/L. With rapid stirring, 75 L of a 5 g/L solution of biotin-N-hydroxysuccimide ester in dimethyl sulfoxide (J. T. Baker Chemical Co., Phillipsburg, NJ 08865) is added to 1.0 mL of antibody solution and allowed to react for 1 h at room temperature. 
Results
Sensitivity and specificity.
This hepatitis EIA test is a solid-phase "sandwich" type simultaneous assay. The test ingredients consist of mouse monoclonal anti-HBs (5D3)-coated polystyrene beads and biotin-labeled mouse monoclonal anti-HBs (5C3 and 5C11) as the first conjugate. On addition of a specimen containing HBsAg, antigen-antibody complexes are formed. After washing with distilled water, avidin-peroxidase is added to the system as the second conjugate. Because of the high affinity between biotin and avidin, the avidin-peroxidase conjugate is bound to the biotin on the antigen-antibody complex, and, after this is washed with distilled water, hydrogen peroxide and 0-phenylenediamine are introduced. When the incubation is completed, 0.5 mol/L sulfuric acid is added to terminate the enzyme-substrate reaction and to "stabilize" the color that has developed. In the absence of HBsAg, antigen is not available for binding to the solid-phase anti-HBs and biotinylated anti-HBs; consequently, no color develops. The three assay procedures-overnight (18 h), the "standard" (4 h), and "stat" (1#{189} h)-meet the requirements for a thirdgeneration test against the current FDA reference panel (Table 1) .
measuring the absorbance at 280 nm, we calculated the efficiency of biotinylation as follows: % efficiency = 100 x (total g applied to column -total tg unbound)/total pg applied Efficiencies were always 80%.
Coupling of avidin to enzyme.
Avidin was coupled to horseradish peroxidase by the procedure of Nakane (8 Abbott). The presence of HBsAg in all immune-complex samples is confirmed by the confirmatory test (see below).
Assay procedure.
Three assay procedures have been developed, which differ only in incubation times: a "stat" assay (1'/2 h total procedure time), a standard assay (4 h), and an overnight assay (18 h).
A polystyrene bead coated with monoclonal antibody is incubated Figure 1 illustrates the sensitivity of the three procedures as used with serial dilutions of HBsAg in recalcified normal human plasma (Paul Ehrlich Institut panel). Evidently the overnight procedure is more sensitive than the standard procedure, which in turn is more sensitive than the stat procedure, and the results illustrate the quantitative nature of the dose-response relationship of the assay for both HBsAg/ad and HBsAg/ay subtypes, respectively. The reactivity of this assay is seen to be similar for the two major subtypes. The assay is sensitive to subnanogram amounts, and it has a wide measuring range, approximately 20 ng to 7.5 g of HBsAg per liter. Only at very high HBsAg concentrations (e.g., >100 mgIL) is the "hook effect" observed ( Figure 2 ). Sample concentrations of approximately 7.5 g of HBsAg per liter are still well above the positive/negative cutoff value.
In clinical testing, by using a positive/negative cutoff value derived from the mean absorbance of the negative control at 492 nm with addition of the factor 0.050 A for the overnight and standard procedures, or 0.025 A for the stat procedure, we observed no false-positive results in more than 2000 clinical specimens. We also investigated all the clinical specimens tested by another approved third-generation HBsAg EIA, the Abbott Auszyme II, and found no discrepant results.
The specificity of the present assay for adw2, adw4, adr, ayw2, ayw3, and ayr subtypes was also examined; all were reactive.
Precision.
Within-run and between-run precision were determined by assaying four HBsAg-containing samples in 
Anticoagulant
effects. The effect of various anticoagulants on the results of the assay was tested by adding an equal amount of HBsAg to the plasma derived from each anticoagulant and assaying by the 4-h standard test procedure. Analytical recovery of HBsAg, which is calculated by using results for serum as the reference, exceeded 93% for plasma treated with heparin, oxalate, or citrate. Both EDTA-treated plasma and serum from a serum-separation tube showed poor HBsAg recovery (Table 2) , and these sorts of samples should not be used in the assay.
Detection of immune complexes.
Similar to the monoclonal-antibody hepatitis RIA, the monoclonal hepatitis EIA described here is reactive with some serum samples that are positive for anti-HBs (Aus, Abbott) and anti-HBc (coRAB, Abbott), suggesting that the monoclonal EJA may detect HBsAg-associated determinants in HBsAg-anti-HBs immune-complex form. Further to explore this possibility, we prepared HBsAg-anti-HBs immune complexes in situ with serum from chronic HBsAg carriers and added high-titer human anti-HBs (from a pool of high-titered donors). As illustrated in Figure 3 , when high-titer human anti-HBs was added to serum from an HBsAg carrier, the monoclonal EIA remained positive up to a 10-fold greater dilution than did the Auszyme II. These data indicate that the monoclonal EIA can recognize their specific antigenic determinants in the immune complexes when HBsAg is no longer detectable by polyclonal anti-HBs antibodies.
All immune-complex samples are confirmed for the presence of HBsAg by the confirmatory test.
Discussion
The application of monoclonal-antibody techniques to the RIA of hepatitis B surface antigen has been previously described (3,4) . The exquisite specificity and high affinities of these antibodies toward HBsAg-associated determinants has permitted the development of RIAs with improved sensitivity.
Furthermore, the monoclonal-antibody RIAs can detect viral epitopes in HBsAg-anti-HBs immunecomplex forms that are undetectable by other commercial polyclonal immunoassays (4) . The presence of immune As such, this assay should provide new information regarding the role of circulating HBsAg immune complex in the epidemiology and evolution of infection with hepatitis B virus. Furthermore, a simple, reproducible, and antigen-specific method is now available for detection of I{BsAg immune complexes rather than (or in addition to) antigen-nonspecific techniques such as the radiolabeled C1qPEG assay (12), the Raji-cell assay (15), and the like.
We have described here our efforts to develop a nonisotopic EIA for HBsAg by using these highly specific monoclonal antibodies. Initial development of an EIA utilizing antibody directly coupled to enzyme (such as 5C3-peroxidase, 5C11-peroxidase) resulted in a less-sensitive assay ( 2.0 gIL). The present amplified two-site monoclonal antibody EIA for hepatitis represents a significant improvement over the direct conjugate assay and is an alternative approach for in vitro immunoassays in general. This system takes advantage of the high affinity of biotin for avidin (dissociation constant, Kd = 105mo1'), a glycoprotein having an apparent molecular mass of 68 000 Da and four biotin-binding sites (16). Because many biotin molecules can be covalently coupled to an antibody, the biotinylated antibody can bind more than one molecule of avidin, hence the amplification achieved through multiple site binding.
In conclusion, the EIA described here has good precision, sensitivity, reproducibility, and practicability, and it can be used as an alternative to RIA.
